Search
Feed aggregator
AstraZeneca Caps US Inhaler Out-of-Pocket Costs on Heels of Boehringer
AstraZeneca Caps US Inhaler Out-of-Pocket Costs on Heels of Boehringer 3/18/2024
Madrigal’s Rezdiffra Energizes MASH Space, Sets Bar for Future Therapies
Madrigal’s Rezdiffra Energizes MASH Space, Sets Bar for Future Therapies 3/18/2024
FDA Action Alert: Orchard, ITF, Merck and More
FDA Action Alert: Orchard, ITF, Merck and More 3/18/2024
Opinion: I Know I Want to Implement AI in My Company’s R&D. What Now?
Opinion: I Know I Want to Implement AI in My Company’s R&D. What Now? 3/18/2024
Bayer and Aignostics to collaborate on next generation precision oncology
Bayer and Aignostics GmbH announced a strategic collaboration on several artificial intelligence (AI)-powered approaches with applications in precision oncology drug research and development. Aignostics is a spin-off from one of the world's leading hospitals, Charité-Universitätsmedizin Berlin, and a global leader in using computational pathology to transform complex biomedical data into biology insights.
FDA Adcomm Backs J&J’s Carvykti, BMS’s Abecma Early in Multiple Myeloma
FDA Adcomm Backs J&J’s Carvykti, BMS’s Abecma Early in Multiple Myeloma 3/15/2024
Merck’s Keytruda Pushes Towards Earlier Stages of Cervical Cancer with Phase III Data
Merck’s Keytruda Pushes Towards Earlier Stages of Cervical Cancer with Phase III Data 3/15/2024
Biotheus, Hansoh Expand Partnership in $694M ADC Deal
Biotheus, Hansoh Expand Partnership in $694M ADC Deal 3/15/2024
Astellas Backs Out of Potential $340M Licensing Deal with Cartesian
Astellas Backs Out of Potential $340M Licensing Deal with Cartesian 3/15/2024
Bayer, AI-Focused Aignostics Partner to Find New Oncology Targets
Bayer, AI-Focused Aignostics Partner to Find New Oncology Targets 3/15/2024
Asgard Gets $32M Series A Backing from J&J, Novo and Boehringer
Asgard Gets $32M Series A Backing from J&J, Novo and Boehringer 3/15/2024
BMS’s Breyanzi Becomes First CAR-T Therapy for Two Types of Leukemia
BMS’s Breyanzi Becomes First CAR-T Therapy for Two Types of Leukemia 3/15/2024
FDA Adcomm to Tackle Complexity of CAR-T for Multiple Myeloma
FDA Adcomm to Tackle Complexity of CAR-T for Multiple Myeloma 3/15/2024
NASH or MASH: No Matter What You Call It, Madrigal’s FDA Approval Is a Big Deal
NASH or MASH: No Matter What You Call It, Madrigal’s FDA Approval Is a Big Deal 3/15/2024
BeiGene’s Tevimbra Wins First US Approval Following Tough Regulatory Path
BeiGene’s Tevimbra Wins First US Approval Following Tough Regulatory Path 3/15/2024
FDA Adcomm Backs Geron’s Anemia Drug for Blood Cancer
FDA Adcomm Backs Geron’s Anemia Drug for Blood Cancer 3/15/2024
FDA Approves Madrigal’s Rezdiffra as First MASH Therapy
FDA Approves Madrigal’s Rezdiffra as First MASH Therapy 3/15/2024
AstraZeneca to acquire Amolyt Pharma, expanding late-stage rare disease pipeline
AstraZeneca announced that it has entered into a definitive agreement to acquire Amolyt Pharma, a clinical-stage biotechnology company focused on developing novel treatments for rare endocrine diseases.
The proposed acquisition will bolster the Alexion, AstraZeneca Rare Disease late-stage pipeline and expand on its bone metabolism franchise with the notable addition of eneboparatide (AZP-3601), a Phase III investigational therapeutic peptide with a novel mechanism of action designed to meet key therapeutic goals for hypoparathyroidism.
AstraZeneca Boosts Rare Disease Portfolio with $1.05B Amolyt Acquisition
AstraZeneca Boosts Rare Disease Portfolio with $1.05B Amolyt Acquisition 3/14/2024
BIO Boots WuXi AppTec from Trade Group Amid US National Security Concerns
BIO Boots WuXi AppTec from Trade Group Amid US National Security Concerns 3/14/2024
World Pharma News
- Novel inhibitor insights offer pathway to preventing PXR-associated drug resistance
- Herpes cure with gene editing makes progress in laboratory studies
- Scientists pinpoint new vaccine "booster" that promotes potent anti-tumour immunity
- New treatment could reverse hair loss caused by an autoimmune skin disease
- AI predicts tumor-killing cells with high accuracy